Making tumor necrosis factor blockers safer: A prescribed consumptive challenge

Journal of Rheumatology

Volumn 35, Issue 7, 2008, Pages 1238-1239

  Keane, Joseph ^a   Cheallaigh, Cliona Ní ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BCG VACCINE; INFLIXIMAB; ISONIAZID; TUMOR NECROSIS FACTOR BLOCKER;

CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DRUG SAFETY; EDITORIAL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; IMMUNE SYSTEM; INFECTION RISK; LATENT TUBERCULOSIS INFECTION; MASS SCREENING; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK ASSESSMENT; TUBERCULIN TEST; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; HUMANS; RHEUMATIC DISEASES; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47349088146     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (21)

1. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
2. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6.
3. Beglinger C, Dudler J, Mottet C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med Wkly 2007;137:620-2.
4. Ormerod LP, Milburn HJ, Gillespie S, et al. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
5. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
6. Mariette X, Salmon D. French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers [abstract]. Ann Rheum Dis 2003;62:791.
7. Kavanagh PM, Gilmartin JJ, O'Donnell J, O'Flanagan D. Tumour necrosis factor-alpha and tuberculosis: guidance from the National TB Advisory Committee. Ir Med J 2008;101:6-7.
8. Raval A, Akhavan-Toyserkani G, Brinker A, et al. Brief communication: Characteristics of spontaneous cases of tuberculosis associated with infliximab. Ann Intern Med 2007;147:699-702.
9. Gomez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Care Res 2007;57:756-61.
10. Perez J, Kupper H, Spencer-Green G. Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe [abstract]. Ann Rheum Dis 2005;64 Suppl 3:265.
11. Mow WS, Abreu-Martin MT, Papadakis KA, et al. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-13.
12. Coaccioli S, Di Cato L, Marioli D, et al. Impaired cutaneous cell-mediated immunity in newly diagnosed rheumatoid arthritis. Panminerva Med 2000;42:263-6.
13. Richeldi L. An update on the diagnosis of tuberculosis infection. Am J Respir Crit Care Med 2006;174:736-42.
14. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005;54:49-55.
15. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis A. Usefulness of enzyme linked immunospot assay (ELISPOT) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-6.
16. Matulis G, Jüni P, Villiger PMG, et al. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90.
17. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11.
18. Cobanoglu N, Kiper N, Dilber E, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007;11:1177-82.
19. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26.
20. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982;60:555-64.
21. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R.T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007;7:428-38.